A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-18.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.
Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 35th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 3, and was the 19th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 39 interventional studies. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 39 have an industry lead sponsor. The 9 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 133rd largest by enrollment of the 149 interventional ones that give a count, is one of 14 that started in 2012, is one of 54 in phase 3, and was the 138th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy of insulin decludec with insulin glargine on glycaemic control using continuous glucose monitoring in patients with type 1 diabetes.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 24 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec
Drug: insulin glargine
Administered subcutaneously (s.c., under the skin) once daily.
Administered subcutaneously (s.c., under the skin) once daily.
Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)
Time within the glycaemic target range \[\> 70 mg/dL (3.9 mmol/L) and \< 130 mg/dL (7.2 mmol/L)\] measured by Continuous Glucose Monitoring (CGM) in the last four hours of each dosing interval during the last 2 weeks of the 6-week treatment period.
Time frame: CGM occured during the last 2 weeks of the 6 weeks treatment period.
Mean Interstitial Glucose (IG) Based on 14 Days of CGM
The observed mean of IG profile was obtained as the average value of area under the IG profile divided by the actual assessment time interval during the last 2 weeks of the 6-week treatment period.
Time frame: CGM monitoring occurred during the last 2 weeks of the 6-week treatment period.
Fasting Plasma Glucose (FPG)
FPG after 6 weeks of treatment in each treatment period.
Time frame: At the end of each 6 week treatment period.
Glycosylated Haemoglobin (HbA1c)
HbA1c after 6 weeks of treatment in each treatment period.
Time frame: At the end of each 6 week treatment period.
Number of Treatment Emergent Adverse Events (AEs)
Number of treatment emergent adverse events (TEAEs). An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.
Time frame: Within each week 6 treatment period
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product (IMP), and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Hypoglycemic episodes reported within each 6 week treatment period.
The trial was conducted at one site in the United States of America (USA).
| Milestone | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Started | 12 | 12 |
| Exposed | 12 | 12 |
| Completed | 12 | 11 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Started | 12 | 11 |
| Exposed | 12 | 11 |
| Completed | 12 | 11 |
| Not completed | 0 | 0 |
Time within the glycaemic target range \[\> 70 mg/dL (3.9 mmol/L) and \< 130 mg/dL (7.2 mmol/L)\] measured by Continuous Glucose Monitoring (CGM) in the last four hours of each dosing interval during the last 2 weeks of the 6-week treatment period.
| hours | IDeg | IGlar |
|---|---|---|
| Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL) | 1.39 ± 0.71 | 1.09 ± 0.77 |
The observed mean of IG profile was obtained as the average value of area under the IG profile divided by the actual assessment time interval during the last 2 weeks of the 6-week treatment period.
| mmol/L | IDeg | IGlar |
|---|---|---|
| Mean Interstitial Glucose (IG) Based on 14 Days of CGM | 9.6 ± 1.5 | 9.8 ± 1.7 |
FPG after 6 weeks of treatment in each treatment period.
| mmol/L | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Treatment period A | 8.8 ± 4.6 | 10.9 ± 4.8 |
| Treatment period B | 10.4 ± 3.4 | 10.9 ± 4.4 |
HbA1c after 6 weeks of treatment in each treatment period.
| percentage of glycosylated haemoglobin | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Treatment period A | 6.6 ± 0.5 | 7.1 ± 0.6 |
| Treatment period B | 6.9 ± 0.7 | 7.3 ± 0.6 |
Number of treatment emergent adverse events (TEAEs). An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.
| events | IDeg | IGlar |
|---|---|---|
| Adverse Events | 18 | 16 |
| Serious Adverse Events | 0 | 0 |
| Severe Adverse Events | 3 | 0 |
| Moderate Adverse Events | 5 | 0 |
| Mild Adverse Events | 10 | 16 |
| Fatal Adverse Events | 0 | 0 |
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product (IMP), and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.
| events | IDeg | IGlar |
|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes | 283 | 239 |
Collected over Treatment emergent adverse events were collected during each 6 week treatment period + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg | — | 0/23 (0%) | 0/23 (0%) |
| IGlar | — | 0/24 (0%) | 8/24 (33.3%) |
| Event | IDeg | IGlar |
|---|---|---|
| NasopharyngitisInfections and infestations | 0/23 | 8/24 |
| Age, Continuous(years) | Full Analysis Set |
|---|---|
| Mean | 45.3 ± 14.9 |
| Sex: Female, Male(Participants) | Full Analysis Set |
|---|---|
| Female | 9 |
| Male | 15 |
| Fasting Plasma Glucose (FPG)(mmol/L) | Full Analysis Set |
|---|---|
| Mean | 10.7 ± 3.4 |
| Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | Full Analysis Set |
|---|---|
| Mean | 7.1 ± 0.6 |
The record gives a start of Apr 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 3 years after primary completion. A results delay was requested in Dec 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec